SCHEMBL4859841

SCHEMBL4859841

COc1ccccc1-c1cc(N)[nH]n1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 4/20 0.58
ALDH1A1 P00352 8/20 0.54
GAA P10253 3/20 0.54
METAP2 P50579 1/20 0.53
HSP90AA1 P07900 2/20 0.53
HSP90AB1 P08238 1/20 0.51
KDM4E B2RXH2 4/20 0.49
HPGD P15428 2/20 0.48
MAPT P10636 1/20 0.48
ALOX15 P16050 1/20 0.48
ALOX12 P18054 1/20 0.48
NPC1 O15118 1/20 0.46
MAPK1 P28482 2/20 0.45
DCUN1D1 Q96GG9 1/20 0.45
MEN1 O00255 1/20 0.45
PPARG P37231 1/20 0.45
KMT2A Q03164 1/20 0.45
NCOA2 Q15596 1/20 0.45
NCOA1 Q15788 1/20 0.45
RXFP1 Q9HBX9 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31324689 1.00 HSD17B10 (0.58) HSD17B10ALDH1A1GAAMETAP2HSP90AA1
SCHEMBL2056464 0.83 MEN1 (0.49) HSD17B10ALDH1A1GAAKDM4EMAPT
SCHEMBL12536447 0.83 ALDH1A1 (0.49) HSD17B10ALDH1A1GAAKDM4EHPGD
SCHEMBL17380970 0.83 TLR8 (0.44) HSD17B10ALDH1A1GAAHSP90AA1HSP90AB1
SCHEMBL3362266 0.81 KDM4E (0.60) HSD17B10ALDH1A1GAAMETAP2HSP90AA1
SCHEMBL6229280 0.81 ALPL (0.62) HSD17B10ALDH1A1GAAKDM4EHPGD
SCHEMBL17380968 0.81 NCOA1 (0.45) HSD17B10GAAKDM4ENPC1NCOA1
SCHEMBL12536509 0.80 PDE5A (0.45) HSD17B10ALDH1A1GAAKDM4EHPGD
SCHEMBL14731246 0.80 SCN9A (0.51) HSD17B10GAAMETAP2KDM4EMAPT
SCHEMBL1856664 0.80 ALDH1A1 (0.57) HSD17B10ALDH1A1KDM4EHPGDPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250145628-A1 PYRAZOLOPYRIMIDINES, COMPOSITIONS COMPRISING THEM AND USES THEREOF NOVO NORDISK A/S (DK) 2025-05-08 US disclosed
WO-2025064210-A1 INHIBITORS OF BILIVERDIN REDUCTASE B (BLVRB) BLOOD CELL TECHNOLOGIES, LLC (US) 2025-03-27 WO disclosed
EP-4479402-A1 PYRAZOLOPYRIMIDINES, COMPOSITIONS COMPRISING THEM AND USES THEREOF Novo Nordisk A/S (DK) 2024-12-25 EP disclosed
WO-2023155004-A1 PYRAZOLOPYRIMIDINES, COMPOSITIONS COMPRISING THEM AND USES THEREOF INVERSAGO PHARMA INC. (CA) 2023-08-24 WO disclosed
WO-2023155004-A1 PYRAZOLOPYRIMIDINES, COMPOSITIONS COMPRISING THEM AND USES THEREOF INVERSAGO PHARMA INC. (CA) 2023-08-24 WO disclosed
US-9969741-B2 Pyrazolotriazines as inhibitors of nucleases MASARYKOVA UNIVERZITA (CZ) 2018-05-15 US disclosed
US-9969741-B2 Pyrazolotriazines as inhibitors of nucleases MASARYKOVA UNIVERZITA (CZ) 2018-05-15 US disclosed
EP-2957562-B1 PYRAZOLOTRIAZINES AS INHIBITORS OF NUCLEASES UNIV MASARYKOVA (CZ) 2017-12-20 EP disclosed
US-20170217923-A1 THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2017-08-03 US disclosed
US-20170217923-A1 THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2017-08-03 US disclosed
US-20130053341-A1 THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL COMPANY (JP) 2013-02-28 US disclosed
EP-2415840-A1 NOVEL AZOMETHINE COMPOUND AND THERMAL TRANSFER SHEET USING THE SAME AZOMETHINE COMPOUND PIGMENT Dai Nippon Printing Co., Ltd. (JP) 2012-02-08 EP disclosed
US-20110129624-A1 NOVEL AZOMETHINE COMPOUND AND THERMAL TRANSFER SHEET USING COLORING MATTER OF THE AZOMETHINE COMPOUND DAI NIPPON PRINTING CO., LTD. (JP) 2011-06-02 US disclosed
US-20110129624-A1 NOVEL AZOMETHINE COMPOUND AND THERMAL TRANSFER SHEET USING COLORING MATTER OF THE AZOMETHINE COMPOUND DAI NIPPON PRINTING CO., LTD. (JP) 2011-06-02 US disclosed
US-7393870-B2 3-(heteroarylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. (US) 2008-07-01 US disclosed
US-20060074116-A1 3-(Heteroarylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2006-04-06 US disclosed
US-7005444-B2 3-(heteroarylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. (US) 2006-02-28 US disclosed
US-20030130328-A1 3-(Heteroarylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2003-07-10 US disclosed
US-6559173-B1 organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation. ALLERGAN, INC. 2003-05-06 US disclosed
WO-2003026650-A1 3-(HETEROARYLAMINO)METHYLENE-1,3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS ALLERGAN, INC. (US) 2003-04-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110129624-A1 NOVEL AZOMETHINE COMPOUND AND THERMAL TRANSFER SHEET USING COLORING MATTER OF THE AZOMETHINE COMPOUND INMT, MNS1, IK HSD17B10 3335/4885ALDH1A1 1335/4885GAA 4760/4885
US-20250145628-A1 PYRAZOLOPYRIMIDINES, COMPOSITIONS COMPRISING THEM AND USES THEREOF CNR1, CNR2, TRPV1 HSD17B10 4155/4885ALDH1A1 1990/4885GAA 4654/4885
US-20060074116-A1 3-(Heteroarylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 HSD17B10 3354/4885ALDH1A1 2360/4885GAA 2732/4885
US-20130053341-A1 THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE PPP4C, PPP3CB, PTPRG HSD17B10 2306/4885ALDH1A1 2732/4885GAA 1062/4885
US-20030130328-A1 3-(Heteroarylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 HSD17B10 3354/4885ALDH1A1 2360/4885GAA 2732/4885
US-20170217923-A1 THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE PPP4C, PTPRG, PPP2CA HSD17B10 2489/4885ALDH1A1 2216/4885GAA 339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.